Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Stoke Therapeutics, Inc. (STOK)

7.65   -0.22 (-2.8%) 03-24 16:00
Open: 7.82 Pre. Close: 7.87
High: 7.82 Low: 7.215
Volume: 272,999 Market Cap: 338(M)

Technical analysis

as of: 2023-03-24 4:30:13 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 10.43     One year: 11.66
Support: Support1: 7.21    Support2: 6
Resistance: Resistance1: 8.92    Resistance2: 9.98
Pivot: 8.77
Moving Average: MA(5): 7.99     MA(20): 8.77
MA(100): 9.07     MA(250): 12.77
MACD: MACD(12,26): -0.3     Signal(9): -0.2
Stochastic oscillator: %K(14,3): 8.3     %D(3): 6.8
RSI: RSI(14): 34.1
52-week: High: 24.96  Low: 6.88
Average Vol(K): 3-Month: 334 (K)  10-Days: 286 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ STOK ] has closed above bottom band by 4.6%. Bollinger Bands are 8.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 7.83 - 7.89 7.89 - 7.94
Low: 7.09 - 7.16 7.16 - 7.2
Close: 7.56 - 7.67 7.67 - 7.74

Company Description

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

Headline News

Thu, 23 Mar 2023
Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Consensus ... - MarketBeat

Wed, 15 Mar 2023
Stoke Therapeutics Says US FDA to Approve Higher Single Dose of Proposed Dravet Syndrome Treatment -

Wed, 15 Mar 2023
Stoke Therapeutics Announces That FDA Will Allow the ... - Business Wire

Wed, 08 Mar 2023
Even after rising 5.6% this past week, Stoke Therapeutics (NASDAQ:STOK) shareholders are still down 56% over the past year - Simply Wall St

Mon, 06 Mar 2023
Stoke Therapeutics Reports Fourth Quarter and Full Year 2022 ... - Business Wire

Mon, 06 Mar 2023
Stoke Therapeutics, Inc. (STOK) Reports Q4 Loss, Tops Revenue ... - Nasdaq

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 39 (M)
% Held by Insiders 1.472e+007 (%)
% Held by Institutions 6.2 (%)
Shares Short 3,840 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -1.0053e+008
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -1
Return on Assets (ttm) 113.1
Return on Equity (ttm) -24
Qtrly Rev. Growth 9.14e+006
Gross Profit (p.s.) 0
Sales Per Share -113.05
EBITDA (p.s.) 0
Qtrly Earnings Growth -2.1
Operating Cash Flow 0 (M)
Levered Free Cash Flow -26 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0.1
Price to Book value 0
Price to Sales -0.07
Price to Cash Flow 0.47

Stock Dividends

Dividend 0
Forward Dividend 3.82e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.